Welcome to our dedicated page for Corbus Pharmaceuticals Holdings news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company dedicated to creating innovative therapies for rare, chronic, and serious inflammatory and fibrotic diseases. The company's leading product candidate, Resunab™, is a pioneering oral anti-inflammatory drug designed to resolve inflammation through an endogenous pathway. Resunab™ is set to begin three Phase 2 clinical trials in 2015 targeting cystic fibrosis, diffuse systemic sclerosis (scleroderma), and dermatomyositis, all conditions where inflammation significantly contributes to disease progression. Additionally, Resunab™ has the potential to address other rare inflammatory diseases.
Corbus Pharmaceuticals is also a precision oncology company with a diversified portfolio aimed at tackling serious illnesses using scientific approaches to well-known biological pathways. The company's development pipeline includes several key candidates:
- CRB-701: A next-generation antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells, releasing a cytotoxic payload.
- CRB-601: An anti-integrin monoclonal antibody blocking TGFβ activation expressed on cancer cells.
- CRB-913: A second-generation, peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Recent developments include the FDA clearance of CRB-601 for a Phase 1 study expected to enroll the first patient in the summer of 2024. Additionally, the company completed a public offering in February 2024, raising $94.5 million, and reported $127 million in cash, cash equivalents, and investments as of February 2, 2024, extending their cash runway through March 31, 2027.
Corbus aims to use the net proceeds from their recent underwritten offering to further their clinical development pipeline, ensuring robust progress across their range of innovative therapies. The company's partnerships and collaborations, such as with CSPC Pharmaceutical Group, highlight their commitment to advancing their pipeline and translating scientific discoveries into effective treatments for patients worldwide.
Headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals is at the forefront of the biotechnology field, continuously striving to bring first-in-class treatments to market, thereby addressing unmet medical needs and improving patient outcomes. For more information, visit corbuspharma.com.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented new pre-clinical data for CRB-913, its CB1 inverse agonist, at Obesity Week 2024. Key findings show CRB-913's brain levels are 15-fold lower than monlunabant, with a 10 times higher plasma-to-brain ratio. The compound demonstrated significant weight loss of up to 38% in DIO mice at doses ranging from 5 to 80 mg/kg/day. Notably, when replacing semaglutide treatment, CRB-913 maintained weight loss and doubled fat reduction compared to semaglutide maintenance. The company plans to begin Phase 1 clinical trials in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event, which runs from November 11-13, 2024. Dr. Cohen's fireside chat is scheduled for November 12, 2024, at 10:00 a.m. ET, and will be available via webcast.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY. The company's Chief Medical Officer, Dr. Dominic Smethurst, will be part of a panel discussion titled 'Capitalizing on Validated Mechanism in Oncology' at 1:30 pm ET.
Additionally, Dr. Smethurst and Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, will be available for one-on-one investor meetings during the event. Interested parties are advised to contact their BMO Capital Markets sales representative for registration details.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York City. The company's CEO, Yuval Cohen, Ph.D., will be presenting at the event.
Key details of the presentation include:
- Date: September 17, 2024
- Time: 8:00 AM Eastern Time
- Location: InterContinental New York Barclay Hotel
- Format: Fireside chat with Cantor analyst Prakhar Agrawal
Dr. Cohen will also be available for one-on-one investor meetings during the conference. A webcast link for the presentation has been provided for those unable to attend in person.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Winston Kung to its Board of Directors, effective August 16, 2024. Mr. Kung, who will also chair the Audit Committee, brings over 20 years of leadership experience in life sciences and investment banking. Currently serving as CFO of Arrivent BioPharma, he has held senior positions at PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, and Amgen.
The company's leadership expressed enthusiasm for Mr. Kung's expertise in pharma industry and capital markets, viewing his appointment as valuable for advancing Corbus' pipeline. Simultaneously, Avery "Chip" Catlin has resigned from the Board and as Audit Committee Chair after serving for over ten years.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. CRB-701: Encouraging Phase 1 data presented at ASCO 2024, showing 44% ORR in metastatic urothelial cancer and 43% ORR in cervical cancer. Phase 1 dose escalation underway in USA and Europe.
2. CRB-913: Phase 1 study for obesity treatment expected to commence in Q1 2025.
3. CRB-601: FDA cleared IND, Phase 1 study expected to initiate in Q4 2024.
4. Financial Results: Net loss of $10.0 million for Q2 2024. Cash, cash equivalents, and investments of $147 million as of June 30, 2024, expected to fund operations through Q3 2027.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in two upcoming investor conferences in August 2024. CEO Yuval Cohen, Ph.D., will provide corporate updates and engage in investor meetings at these events:
1. BTIG Virtual Biotechnology Conference (August 5-6, 2024): Invitation-only, one-on-one investor meetings.
2. Wedbush PacGrow Healthcare Conference (August 13-14, 2024): Invitation-only, one-on-one and small group investor meetings.
Interested investors should contact their respective BTIG or Wedbush representatives to arrange meetings with Corbus management during these conferences.
Corbus Pharmaceuticals announced promising clinical data for SYS6002 (CRB-701), a Nectin-4 targeting antibody drug conjugate, during the ASCO 2024 conference.
The Phase 1 trial has enrolled 37 patients since January 2024, with 25 evaluated for efficacy. SYS6002 showed a 44% ORR and 78% DCR in metastatic urothelial cancer (mUC), and a 43% ORR and 86% DCR in cervical cancer at doses ≥ 1.2 mg/Kg.
No dose-limiting toxicities were observed up to 4.5 mg/Kg. Notable adverse events included three cases of skin rash and one instance of grade 1 neuropathy, all resolved. Pharmacokinetic data demonstrated lower free MMAE levels than enfortumab vedotin across all doses.
The trial continues to show SYS6002's safety and efficacy, with the U.S. clinical study expected to complete in Q4 2024, with data presentation in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update at the 45th Annual Goldman Sachs Global Healthcare Conference in Miami Beach, FL, from June 10-13, 2024. The presentation is scheduled for June 12, 2024, at 2:40 p.m. ET. Investors will have the opportunity to participate in one-on-one meetings with the CEO. The presentation will be webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that an abstract titled 'Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701)' will be presented at the 2024 ASCO Annual Meeting. This presentation will occur on June 1, 2024, and will provide updated clinical data from a Phase 1 trial. The trial involves dose escalation spanning seven levels and employs a Bayesian Optimal Interval design. The study aims to establish the Maximum Tolerated Dose (MTD) and Phase 2 dose for SYS6002 (CRB-701) in patients with advanced solid tumors unresponsive to standard treatments. Key findings include safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The study is conducted in China by Corbus's partner CSPC, with a parallel Phase 1 study recently initiated in the U.S., where the first patient was dosed in April 2024.
FAQ
What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?
What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?
What diseases does Corbus Pharmaceuticals target?
What is Resunab™?
What are the key products in Corbus’ development pipeline?
Where is Corbus Pharmaceuticals headquartered?
What recent financial developments has Corbus Pharmaceuticals announced?
Who are Corbus Pharmaceuticals’ partners?
When is Corbus Pharmaceuticals expected to begin the Phase 1 study of CRB-601?
What is the focus of CRB-701?
What is the purpose of the recent underwritten offering by Corbus Pharmaceuticals?
How can potential investors learn more about Corbus Pharmaceuticals' offerings?
